Related Experiment Video
Updated: Jun 17, 2026
07:25
Ultrasonographic Evaluation of Salivary Glands for Sjogren's Syndrome: Diagnostic and Monitoring Insights
Published on: October 13, 2023
[Current therapeutic options in Sjögren's syndrome]
1Park-Klinik Weissensee, Akademisches Lehrkrankenhaus der Charité, Schönstr. 80, 13086 Berlin. hansen@park-klinik.com
Zeitschrift Fur Rheumatologie
|December 17, 2009
Summary
Sjögren's syndrome lacks effective treatments due to unknown causes. Emerging therapies targeting B-cells, like Rituximab, show promise for managing this autoimmune disease and its complications.
Area of Science:
- Rheumatology
- Immunology
- Systemic inflammatory disorders
Context:
- Sjögren's syndrome is a systemic autoimmune disease with unknown etiology.
- Current treatments primarily manage symptoms and extraglandular manifestations.
- Limited therapeutic options exist for Sjögren's syndrome patients.
Purpose:
- To review current and emerging therapeutic strategies for Sjögren's syndrome.
- To highlight the potential of novel treatment approaches targeting B-cells.
Summary:
- Sjögren's syndrome treatment is largely symptomatic, with conventional therapies including glucocorticoids, NSAIDs, and immunosuppressants for complications.
- Research into Sjögren's pathogenesis is paving the way for targeted therapies.
- B-cell-depletion therapy, exemplified by Rituximab, has demonstrated encouraging results in early clinical trials for Sjögren's patients, including those with lymphoma.
Impact:
- Novel therapeutic strategies targeting B-cells offer new hope for Sjögren's syndrome patients.
- Further research and defined outcome criteria are essential for validating new treatments.
- Advancements in understanding Sjögren's pathogenesis may lead to more effective disease management.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:26Nephrotic Syndrome II : Assessment and Medical Management
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...